Blockchain Registration Transaction Record

HeartBeam's Portable ECG Aims to End Pre-Hospital Cardiac Delays

HeartBeam (NASDAQ: BEAT) develops cable-free, portable 12-lead ECG system to address pre-hospital delay in cardiac care. FDA-cleared for arrhythmia, with heart attack detection planned.

This matters because heart disease remains a leading cause of death globally, and timely detection is crucial for survival. HeartBeam’s technology empowers patients to capture clinical-grade ECG data at home, potentially reducing the dangerous delay between symptom onset and medical intervention. For individuals with intermittent symptoms, this could mean earlier diagnosis, faster treatment, and better outcomes. It also shifts cardiac monitoring from reactive to proactive, giving physicians actionable data that could prevent heart attacks or other acute events.